ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
ASLN was delisted on the 18th of July, 2024.
27 hedge funds and large institutions have $12.8M invested in ASLAN Pharmaceuticals Limited American Depositary Shares in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 10 reducing their positions, and 3 closing their positions.
13% more capital invested
Capital invested by funds: $11.3M → $12.8M (+$1.48M)
0% more funds holding
Funds holding: 27 → 27 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
60% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$64.5K |
| 2 |
CAL
Capital Analysts LLC
Fort Washington,
Pennsylvania
|
+$6.91K |
| 3 |
WW
Waterfront Wealth
Overland Park,
Kansas
|
+$4.85K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$2.58K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$2.58K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$258K |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$170K |
| 3 |
RI
RTW Investments
New York
|
-$151K |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$96.9K |
| 5 |
Renaissance Technologies
New York
|
-$71K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Simplex Trading
Chicago,
Illinois
| $2K | +$2.58K | +100 | +1,111% |
|
27
UBS Group
Zurich,
Switzerland
| $1K | +$1.03K | +40 | New |
|
|
DCM
28
DAFNA Capital Management
Los Angeles,
California
| – | -$170K | -8,593 | Closed |
|
29
Bank of America
Charlotte,
North Carolina
| – | -$44K | -2,204 | Closed |
|
ASLN Hedge Fund Activity: Q3 2022 in Review
27 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) for Q3 2022, worth a combined $12.8M — up 13% from $11.3M a quarter earlier.
Fund positioning in ASLN was balanced in Q3 2022: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 10 trimmed.
The largest buyer was Tang Capital Management, adding an estimated $64.5K. The largest seller was Sabby Management, cutting an estimated $258K.
- 27 institutional investors held ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $12.8M of ASLAN Pharmaceuticals Limited American Depositary Shares stock for Q3 2022, up 13% quarter-over-quarter.
- 3 funds opened new ASLAN Pharmaceuticals Limited American Depositary Shares positions in Q3 2022 and 3 closed out, a net change of 0 holders.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares buyer in Q3 2022 was Tang Capital Management, an estimated $64.5K added.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares seller in Q3 2022 was Sabby Management, an estimated $258K sold.
Based on aggregated 13F filings for Q3 2022.